First preclinical SPECT/CT imaging and biodistribution of [165Er]ErCl3 and [165Er]Er-PSMA-617
This study demonstrated the preclinical use of <sup>165</sup>Er for the first time. Using [<sup>165</sup>Er]ErCl<sub>3</sub> and [<sup>165</sup>Er]Er-PSMA-617 as examples, the radiochemistry, cell, and animal studies showed that <sup>165</sup>Er can be used as a tool for evaluating targeted radiopharmaceuticals. The X-ray emission from <sup>165</sup>Er can be used for quantitative SPECT imaging in mice.
Authors
- Pedro L. Esquinas (ORCID: https://orcid.org/0000-0001-8577-6083)
- Valery Radchenko (ORCID: https://orcid.org/0000-0002-4742-6565)
- Cristina Rodríguez‐Rodríguez (ORCID: https://orcid.org/0000-0002-3313-4422)
- François Bénard (ORCID: https://orcid.org/0000-0001-7995-3581)
- Helen Merkens (ORCID: https://orcid.org/0000-0003-1958-0167)
- Hua Yang (ORCID: https://orcid.org/0000-0003-1833-9515)
- Behrad Saeedi Saghez (ORCID: https://orcid.org/0000-0002-9534-8426)
Institutions
- BC Cancer Agency (CA)
- TRIUMF (CA)
- University of British Columbia (CA)
- Simon Fraser University (CA)
Publication Details
- Journal
- EJNMMI Radiopharmacy and Chemistry
- Published
- 2024-12-18
- DOI
- https://doi.org/10.1186/s41181-024-00312-9
- Citations
- 4
- Primary Topic
- Radiopharmaceutical Chemistry and Applications
- Type
- article
- Field-Weighted Citation Impact
- 1.62
Funders
- Natural Sciences and Engineering Research Council of Canada